TriSalus Life Sciences (TLSI) director granted RSUs and stock options in 2026 award

Rhea-AI Filing Summary

TriSalus Life Sciences director Michael P. Stansky reported new equity awards and updated holdings. He received two grants of restricted stock units covering 20,089 and 23,501 shares of common stock, both payable solely in stock. One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date, while the retainer RSU award vests in three equal quarterly installments through the remainder of 2026, each subject to his continued board service.

He was also granted a director stock option for 47,003 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036, which will fully vest one year after the grant date if he continues serving. Following these grants, he holds 830,722 common shares directly and 199,698 shares indirectly through Skyview Investments LLC, where he serves as managing member with voting and dispositive power, along with 139,540 director stock options.

Insights

Equity compensation analyst

Routine director equity compensation with RSUs and options, no open-market trading.

The transactions for TriSalus Life Sciences reflect standard non-employee director compensation. Michael P. Stansky received RSU grants in lieu of cash board fees and an additional equity award, all at zero purchase price, reinforcing pay alignment with shareholder outcomes rather than signaling active buying or selling.

The RSUs vest over one year and quarterly through 2026, while the option to buy 47,003 shares at $2.52 per share expires in 2036. Because there are no reported sales and these are compensation grants, the informational value for short-term sentiment is limited; the filing mainly updates his equity-based stake in the company.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Stansky Michael P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	47,003	$0.00	--
Grant/Award	Common Stock	23,501	$0.00	--
Grant/Award	Common Stock	20,089	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Director Stock Option (right to buy) — 139,540 shares (Direct, null); Common Stock — 810,633 shares (Direct, null); Common Stock — 199,698 shares (Indirect, By Skyview Investments LLC)

Footnotes (1)

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSU Award 1: 20,089 shares Retainer RSU Award: 23,501 shares Director stock option grant: 47,003 shares at $2.52 +3 more

6 metrics

RSU Award 1 20,089 shares Restricted stock units, vests fully one year after May 14, 2026

Retainer RSU Award 23,501 shares RSUs in lieu of 2026 cash retainer, vest quarterly through 2026

Director stock option grant 47,003 shares at $2.52 Option exercise price $2.52, expires May 13, 2036

Direct common shares after grants 830,722 shares Direct ownership in TriSalus common stock following awards

Indirect common shares via Skyview 199,698 shares Held by Skyview Investments LLC, with Stansky as managing member

Director options outstanding 139,540 options Total director stock options following the 47,003-share grant

Key Terms

restricted stock units, Retainer RSU Award, Non-Employee Director Compensation Policy, Director Stock Option (right to buy), +1 more

5 terms

restricted stock units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Retainer RSU Award financial

"Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer."

Non-Employee Director Compensation Policy financial

"The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy."

Director Stock Option (right to buy) financial

"Director Stock Option (right to buy) with an exercise price of 2.5200 per share and expiration date in 2036."

beneficially own financial

"may be deemed to beneficially own the securities reported herein"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stansky Michael P

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		23,501(1)	A	$0	810,633	D
Common Stock	05/14/2026		A		20,089(2)	A	$0	830,722	D
Common Stock								199,698	I	By Skyview Investments LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$2.52	05/14/2026		A		47,003		(4)	05/13/2036	Common Stock	47,003	$0	139,540	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

2. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.

3. The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.

4. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did TriSalus Life Sciences (TLSI) director Michael P. Stansky receive?

He received two restricted stock unit awards for 20,089 and 23,501 TriSalus (TLSI) shares and a director stock option for 47,003 shares at a $2.52 exercise price. All were granted as compensation, not open-market purchases, and vest based on continued board service.

How do the new RSU grants for TLSI’s Michael P. Stansky vest?

One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date. The separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in each case contingent on his continued service with TriSalus Life Sciences (TLSI).

What are the key terms of Michael P. Stansky’s new stock option in TLSI?

He was granted a director stock option covering 47,003 TriSalus (TLSI) common shares at a $2.52 exercise price, expiring May 13, 2036. The option vests in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.

How many TriSalus (TLSI) shares does Michael P. Stansky hold after these transactions?

After the equity awards, he holds 830,722 TLSI common shares directly and 199,698 shares indirectly through Skyview Investments LLC. He also holds 139,540 director stock options, including the newly granted 47,003-share option, aligning his compensation with long-term equity performance.

What is Skyview Investments LLC’s role in TLSI holdings reported for Michael P. Stansky?

Skyview Investments LLC owns 199,698 TriSalus (TLSI) shares reported as indirect holdings. Michael P. Stansky is the managing member of Skyview, exercising voting and dispositive power over these shares, so they are treated as part of his beneficial ownership in the Form 4 disclosure.